Sean Cahill called on a Monday morning in July.
Not to discuss Mike Ross — that case had been resolved in its own form and Cahill had moved on, as prosecutors did. He was in a different unit now: securities fraud, assigned after the Forstman IG investigation had demonstrated his competence with complex financial-regulatory matters.
"I've been watching the Meridian case," he said.
"I assumed."
"The clinical trial manipulation — did you know it also constitutes securities fraud?"
I'd known this was a possible angle since the algorithm evidence. I'd been deciding whether to push it. "I've been thinking about it."
"Every SEC filing since the FDA approval misstates the drug's safety profile," Cahill said. "Every quarterly earnings report, every investor presentation that cited Corvalox's approved status and revenue trajectory — all of it built on the foundation of falsified clinical data. The investors who bought Meridian stock based on those representations were defrauded." A pause. "I want to file alongside you."
I sat with the offer for a moment.
The prosecutor who had been across the table from me during Mike Ross's plea negotiation. The same methodical, principled attorney who had pushed for accountability while accepting a framework that was actually just. Offering to co-prosecute a pharmaceutical company.
The law made strange allies when the evidence demanded it.
"Tell me what you need," I said.
The coordination meeting was at the SEC's offices on Vesey Street — different building from the IG office where Harvey and I had filed the Blatchford complaint, same federal DNA. Cahill arrived with two attorneys from the securities fraud unit and a forensic accountant named Priya Mehta who had the specific efficiency of someone who read financial documents the way I read case files.
I arrived with Okafor's report and the version history.
We spent three hours on jurisdictional framework.
The terms I negotiated: I controlled the civil litigation narrative, Cahill controlled the criminal referral track and any SEC enforcement action. We shared discovery — all the documents Zane & Roden had produced from the 2.3-terabyte hard drive, plus any new production that resulted from Cahill's federal subpoena authority. But we maintained independent strategic decision-making. Neither side stepped on the other's case theory.
The key asset the SEC brought: federal subpoena power that made Covington's obstruction strategy exponentially more expensive. Every document Meridian tried to protect from a private plaintiff became a potential contempt risk when the SEC was asking for it.
[ Win Rate Calculator: Meridian — government co-plaintiff. Resources: federal subpoena authority, forensic accounting team, criminal referral track. Probability revision: 58% → 65%. Key mechanism: obstruction calculus shifts from strategy to crime when opposing a federal agency. ]
"The Blatchford complaint gave me background on how you operate," Cahill said, during a break. He was standing by the window looking at the harbor. "Joint strategy, clean coordination, principle over leverage."
"It usually produces better outcomes than the alternatives."
"For everyone except the target."
"That's the idea."
He turned from the window. "I want to be clear about something. The criminal track is mine to run. If the grand jury indicts the CMO, that proceeds independently of your civil timeline. I won't hold it to benefit your settlement negotiations."
"I wouldn't ask you to."
"Good." He looked at the documents on the table. "How soon do you plan to depose the CMO?"
"Six weeks."
"Depose him first. Let us review the transcript before the grand jury sees it. If he lies in your deposition, we have the perjury angle."
It was a good piece of strategic thinking. Cahill was less interested in spectacular prosecution than in building airtight cases, which was why Mike's plea had been negotiated cleanly and why he'd accepted my framework. Solid process. Evidence-based. The kind of prosecution that held up on appeal.
"Agreed," I said.
The stay motion arrived three days after the coordination was formalized.
I'd anticipated it — when a criminal investigation opens parallel to a civil case, the defendant's first motion is always a stay: freeze the civil proceedings while the criminal track runs, prevent the plaintiff from obtaining discovery that the criminal defendant has a Fifth Amendment right to withhold.
It was a good argument. Standard, effective, legally supported.
I filed my opposition before Covington finished theirs.
Not a premature filing — I'd drafted the opposition in the two weeks between Cahill's call and the formal coordination, because the stay motion was inevitable and I intended to have the fastest response in the clerk's record.
The argument: the ongoing public health risk to four to six hundred patients on Corvalox justified no delay in the civil proceedings. The pharmaceutical fraud cases I'd cited — three of them, carefully selected for factual similarity — had all proceeded in parallel with criminal investigations without prejudicing the criminal defendants' Fifth Amendment rights. The civil track's discovery would focus on the documentary evidence, not testimony the CMO was entitled to withhold.
Judge Patricia Chen — our assigned judge, who had the specific impatience of a federal judge who had seen every delay tactic in the book and had limited tolerance for ones that dressed up as procedural integrity — scheduled the stay motion for argument in ten days.
She ruled from the bench at the end of the argument session.
"Motion denied. Civil proceedings will continue on the current schedule." She looked at Covington's counsel. "The court notes that the defendants' delay strategy has already produced twelve denied motions. The court expects this to be the last motion that substitutes procedure for substance."
Covington's lead attorney, a man named Warren who had been impeccably composed through every prior motion, wrote something on his legal pad with the controlled expression of a man receiving information he didn't enjoy.
Outside the courthouse, I texted Harvey.
SEC is co-plaintiff in Meridian. Stay motion denied.
His response arrived while I was still on the courthouse steps.
Good.
One word.
From Harvey Specter at 3 PM on a Tuesday, in real time, about a case he had no involvement in. Four years ago, that word would have been calibrated — delivered to establish his assessment of something as a judgment rendered from authority. Now it was just what it said.
Good.
I put the phone in my pocket.
Dr. Rowe called while I was walking to the subway. She'd been monitoring the court docket and had seen the ruling within minutes.
"The stay motion," she said.
"Denied. We're on schedule."
A pause. Not the long silence she'd used in our first meeting, when the weight of what she was doing had required time. A shorter silence, the kind that preceded something specific.
"Does the SEC involvement change what happens to the patients?" she asked.
"The criminal track can produce faster FDA action," I said. "If the grand jury indicts, the FDA will likely initiate an independent safety review of Corvalox as a parallel proceeding. That could produce a patient notification or market withdrawal faster than our civil case alone." I paused. "That was one of the reasons I agreed to coordinate with Cahill."
Another pause.
"Thank you," she said. "For thinking about that."
"That's the job."
I went down into the subway.
The CMO deposition was in five weeks.
Okafor's expert report was filed and in Covington's hands.
The SEC was co-plaintiff with federal subpoena authority and a forensic accounting team reading Meridian's financial disclosures backward.
The stay motion was denied.
Every tactical move Covington had attempted — twelve motions, one stay request, aggressive document production objections — had been met and deflected. Their delay strategy had cost their client time and credibility with the assigned judge and produced nothing.
[ Win Rate Calculator: Meridian — post-stay denial. Current probability: 65%. CMO deposition remains pivotal event. Grand jury timeline: Cahill's control. ]
Sixty-five percent.
Thirteen months ago it had been forty-four.
Not because the odds had gotten better on their own. Because the work had been done: the algorithm discovered, the expert engaged, the SEC coordinated, the stay denied, the CMO's deposition scheduled.
Every percentage point was earned.
The subway car filled at the next stop. I held the pole and read Cahill's follow-up email on my phone — the discovery sharing protocol, the timeline for grand jury presentation, the forensic accounting team's preliminary questions about Meridian's post-approval financial disclosures.
Four to six hundred patients.
Corvalox still on the market.
The CMO still in his office.
Five weeks until the deposition room, and the six-day window, and the eleven threshold parameters that had no legitimate explanation.
The train moved.
Scott Roden kept building.
A LOT More chapters reign FREE upon unwrittenrealm.com.
• Normal | $8 — 15 chapters ahead
• Advanced | $11 — 20 chapters ahead
• Overlord | $19 — 25 chapters ahead, plus request a refinement (plot, character, system) on any of my novels
patreon.com/TheFinex5
▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰
― DECREE ―
More chapters reign FREE upon unwrittenrealm.com.
The throne acknowledges.
▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰